PP
NBIX icon

Prudential plc’s Neurocrine Biosciences NBIX Stock Holding History

Prudential plc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$532K Sell
4,036
-98
-2% -$13K ﹤0.01% 558
2025
Q4 		$586K Buy
4,134
+98
+2% +$14.2K ﹤0.01% 546
2025
Q3 		$567K Hold
4,036
– – ﹤0.01% 578
2025
Q2 		$507K Buy
+4,036
New +$463K ﹤0.01% 629
2024
Q4 		– Sell
-21,119
Closed -$2.43M – 827
2024
Q3 		$2.43M Buy
21,119
+5,586
+36% +$766K 0.01% 372
2024
Q2 		$2.14M Sell
15,533
-2,884
-16% -$396K 0.01% 383
2024
Q1 		$2.54M Sell
18,417
-1,514
-8% -$207K 0.02% 365
2023
Q4 		$2.63M Sell
19,931
-606
-3% -$69.8K 0.03% 358
2023
Q3 		$2.31M Sell
20,537
-209
-1% -$22K 0.03% 344
2023
Q2 		$1.96M Buy
20,746
+10,591
+104% +$1.03M 0.02% 396
2023
Q1 		$1.03M Buy
10,155
+4,257
+72% +$443K 0.01% 544
2022
Q4 		$704K Buy
5,898
+3,628
+160% +$425K 0.01% 666
2022
Q3 		$241K Buy
+2,270
New +$230K ﹤0.01% 769

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Prudential plc's NBIX Position: Q1 2026 in Review

Prudential plc reduced its Neurocrine Biosciences (NBIX) stake by 2.4% in Q1 2026, selling an estimated $13K and leaving 4,036 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #558.

Prudential plc first reported a position in NBIX in Q3 2022 and has held it in 13 quarters since. The position peaked at $2.63M in Q4 2023. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Prudential plc held 4,036 shares of Neurocrine Biosciences worth $532K as of Q1 2026.
  • Prudential plc sold 98 Neurocrine Biosciences shares in Q1 2026, an estimated $13K.
  • Neurocrine Biosciences made up ﹤0.01% of Prudential plc's portfolio in Q1 2026, its #558 holding.
  • Prudential plc first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 13 quarters since.
  • Prudential plc's Neurocrine Biosciences position peaked at $2.63M in Q4 2023.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Prudential plc's 13F filing for Q1 2026, filed 14 May 2026.